Is ADC a rising star in solid tumor? An umbrella review of systematic reviews and meta-analyses
Abstract Background Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the potency of highly cytotoxic drugs and are known as panaceas, completely changing the treatment paradigm for solid tumors. Compared with other anti-cancer drugs, do they have better efficacy...
Saved in:
| Main Authors: | Hua Wei, Yongjun Zhang, Yun Lu, Ya Zou, Lu Zhou, Xiaoli Qin, Qian Jiang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-13726-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The efficacy and safety of biologics for patients with severe asthma: an umbrella review of systematic reviews and meta-analyses
by: Qionghua Xiao, et al.
Published: (2025-05-01) -
Diverse Roles of Antibodies in Antibody–Drug Conjugates
by: Aiko Yamaguchi, et al.
Published: (2025-01-01) -
Global research progress in antibody-drug conjugates for solid tumors: Bibliometrics and visualized analysis
by: Wenjun Fang, et al.
Published: (2025-12-01) -
Antibody-drug conjugates in cancer therapy: applications and future advances
by: Rou Long, et al.
Published: (2025-05-01) -
Editorial: Antibody-drug conjugates in solid and hematologic malignancies
by: Khalil Saleh, et al.
Published: (2025-08-01)